Paul Thielking

Paul Thielking currently serves as the Chief Scientific Officer at Numinus, a position held since June 2022. Prior to this role, Paul was also the Chief Scientific Officer at Novamind from June 2021 to June 2022, where the company focused on providing integrative behavioral health care, particularly emphasizing ketamine-assisted therapy in its network of clinics and clinical research sites. Earlier in their career, Paul worked at the University of Utah as the Director of Psycho-oncology from July 2008 to May 2021, contributing significant expertise in the intersection of mental health and cancer care.